TWI874645B - 作為il-17調節劑之咪唑并嗒類 - Google Patents

作為il-17調節劑之咪唑并嗒類 Download PDF

Info

Publication number
TWI874645B
TWI874645B TW110115268A TW110115268A TWI874645B TW I874645 B TWI874645 B TW I874645B TW 110115268 A TW110115268 A TW 110115268A TW 110115268 A TW110115268 A TW 110115268A TW I874645 B TWI874645 B TW I874645B
Authority
TW
Taiwan
Prior art keywords
alkyl
substituted
compound
pharmaceutically acceptable
acceptable salt
Prior art date
Application number
TW110115268A
Other languages
English (en)
Chinese (zh)
Other versions
TW202208367A (zh
Inventor
史提芬 高伯格
大衛 古門
約翰 凱斯
克瑞格 伍德斯
提姆西 羅雷爾
維吉尼亞 坦尼斯
康納 馬汀
史提芬 梅杜那
斯特凡 麥卡佛
亞歷山大 凡迪斯
史提芬 洛斯科特
道格拉斯 貝海納
亞歷山大 羅維拉
夏綠蒂 德克胡特
曉華 薛
Original Assignee
比利時商健生藥品公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 比利時商健生藥品公司 filed Critical 比利時商健生藥品公司
Publication of TW202208367A publication Critical patent/TW202208367A/zh
Application granted granted Critical
Publication of TWI874645B publication Critical patent/TWI874645B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)
  • Lubricants (AREA)
  • Fats And Perfumes (AREA)
  • Cosmetics (AREA)
TW110115268A 2020-04-30 2021-04-28 作為il-17調節劑之咪唑并嗒類 TWI874645B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063017682P 2020-04-30 2020-04-30
US63/017,682 2020-04-30

Publications (2)

Publication Number Publication Date
TW202208367A TW202208367A (zh) 2022-03-01
TWI874645B true TWI874645B (zh) 2025-03-01

Family

ID=76197556

Family Applications (1)

Application Number Title Priority Date Filing Date
TW110115268A TWI874645B (zh) 2020-04-30 2021-04-28 作為il-17調節劑之咪唑并嗒類

Country Status (20)

Country Link
US (3) US11691979B2 (https=)
EP (1) EP4143195B1 (https=)
JP (1) JP7664947B2 (https=)
KR (1) KR20230019507A (https=)
CN (1) CN115884810B (https=)
AR (1) AR121959A1 (https=)
AU (1) AU2021264528A1 (https=)
BR (1) BR112022021962A2 (https=)
CA (1) CA3181676A1 (https=)
CO (1) CO2022017072A2 (https=)
EC (1) ECSP22091485A (https=)
ES (1) ES3036330T3 (https=)
IL (1) IL297705A (https=)
JO (1) JOP20220284A1 (https=)
MX (1) MX2022013647A (https=)
PE (1) PE20230469A1 (https=)
TW (1) TWI874645B (https=)
UY (1) UY39188A (https=)
WO (1) WO2021222404A1 (https=)
ZA (1) ZA202212967B (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201909190D0 (en) 2019-06-26 2019-08-07 Ucb Biopharma Sprl Therapeutic agents
KR20230019507A (ko) * 2020-04-30 2023-02-08 얀센 파마슈티카 엔.브이. Il-17의 조절제로서의 이미다조피리다진
WO2021220183A1 (en) 2020-04-30 2021-11-04 Janssen Pharmaceutica Nv Imidazopyrimidines as modulators of il-17
CA3200594A1 (en) * 2020-12-14 2022-06-23 UCB Biopharma SRL Imidazopyridazine derivatives as il-17 modulators
WO2023025783A1 (en) 2021-08-23 2023-03-02 Leo Pharma A/S Small molecule modulators of il-17
KR20240082371A (ko) 2021-09-27 2024-06-10 얀센 파마슈티카 엔브이 이미다조피리다진 il-17 억제제 화합물
JP2024536869A (ja) 2021-09-27 2024-10-08 ヤンセン ファーマシューティカ エヌ．ベー． イミダゾピリダジンｉｌ－１７阻害剤化合物
WO2023111181A1 (en) 2021-12-16 2023-06-22 Leo Pharma A/S Small molecule modulators of il-17
CN118580191A (zh) * 2022-01-28 2024-09-03 和记黄埔医药（上海）有限公司 用于制备咪唑并[1,2-b]哒嗪类化合物的中间体
WO2023166172A1 (en) 2022-03-04 2023-09-07 Leo Pharma A/S Small molecule modulators of il-17
EP4525987A1 (en) * 2022-05-19 2025-03-26 Dice Alpha, Inc. Lactam substituted imidazopyridazine il-17a modulators and uses thereof
TW202430165A (zh) 2022-12-02 2024-08-01 丹麥商理奧藥品公司 Il-17之小分子調節劑
CN115806503B (zh) * 2022-12-02 2025-03-07 中国海洋大学 一种选择性组蛋白去乙酰化酶抑制剂及其制备方法和应用
CN121311483A (zh) * 2023-03-28 2026-01-09 詹森药业有限公司 含内酰胺的咪唑并哒嗪il-17抑制剂化合物
KR20250168657A (ko) * 2023-04-11 2025-12-02 다이스 알파, 인크. 치환된 6-이미다조피리다진 il-17a 조정제 및 그의 용도
WO2025202931A1 (en) 2024-03-27 2025-10-02 Janssen Pharmaceutica Nv Imidazopyridazine il-17 inhibitor compounds
WO2025247285A1 (zh) * 2024-05-28 2025-12-04 西藏海思科制药有限公司 一种可抑制il-17a的杂环化合物制备及其用途
WO2026080825A1 (en) * 2024-10-10 2026-04-16 Revolution Medicines, Inc. Synthesis of ras inhibitors

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014039595A1 (en) * 2012-09-06 2014-03-13 Bristol-Myers Squibb Company Imidazopyridazine jak3 inhibitors and their use for the treatment of inflammatory and autoimmune diseases
WO2017087590A1 (en) * 2015-11-18 2017-05-26 Bristol-Myers Squibb Company Imidazopyridazine compounds useful as modulators of il-12, il-23 and/or ifn alpha responses
WO2019138017A1 (en) * 2018-01-15 2019-07-18 Ucb Biopharma Sprl Fused imidazole derivatives as il-17 modulators

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10208349B2 (en) 2011-01-07 2019-02-19 Ucb Biopharma Sprl Lipocalin 2 as a biomarker for IL-17 inhibitor therapy efficacy
US9284283B2 (en) 2012-02-02 2016-03-15 Ensemble Therapeutics Corporation Macrocyclic compounds for modulating IL-17
WO2014066726A2 (en) 2012-10-26 2014-05-01 Ensemble Therapeutics Corporation Compounds for modulating il-17
WO2014181287A1 (en) 2013-05-09 2014-11-13 Piramal Enterprises Limited Heterocyclyl compounds and uses thereof
US10035777B2 (en) 2014-08-05 2018-07-31 Bristol-Myers Squibb Company Heterocyclic kinase inhibitors
GB201709456D0 (en) 2017-06-14 2017-07-26 Ucb Biopharma Sprl Therapeutic agents
WO2019223718A1 (zh) 2018-05-22 2019-11-28 成都先导药物开发股份有限公司 一种免疫调节剂
EP3599245A1 (en) 2018-07-27 2020-01-29 Dompé farmaceutici S.p.A. Il-17a binding polypeptides and medical uses thereof
GB201820166D0 (en) 2018-12-11 2019-01-23 Ucb Biopharma Sprl Therapeutic agents
GB201820165D0 (en) 2018-12-11 2019-01-23 Ucb Biopharma Sprl Therapeutic agents
GB201820316D0 (en) 2018-12-13 2019-01-30 Bicyclerd Ltd Bicyclic peptide ligands specific for IL-17
BR112021010453A2 (pt) 2018-12-19 2021-08-24 Leo Pharma A/S Composto, e, composição farmacêutica
TWI752400B (zh) 2019-01-07 2022-01-11 美商美國禮來大藥廠 Il-17a抑制劑
TWI839461B (zh) 2019-02-06 2024-04-21 美商戴斯阿爾法股份有限公司 Il-17a調節物及其用途
US20220162191A1 (en) 2019-03-08 2022-05-26 Leo Pharma A/S Small molecule modulators of il-17
GB201909190D0 (en) 2019-06-26 2019-08-07 Ucb Biopharma Sprl Therapeutic agents
GB201909191D0 (en) 2019-06-26 2019-08-07 Ucb Biopharma Sprl Therapeutic agents
GB201909194D0 (en) 2019-06-26 2019-08-07 Ucb Biopharma Sprl Therapeutic agents
CN112341441B (zh) 2019-08-09 2022-02-11 成都先导药物开发股份有限公司 一种免疫调节剂
CN112341429B (zh) 2019-08-09 2021-11-23 成都先导药物开发股份有限公司 一种免疫调节剂的中间体化合物
CN112341451B (zh) 2019-08-09 2022-06-17 成都先导药物开发股份有限公司 一种免疫调节剂
WO2021027722A1 (zh) 2019-08-09 2021-02-18 成都先导药物开发股份有限公司 一种免疫调节剂
CN112341442B (zh) 2019-08-09 2021-10-22 成都先导药物开发股份有限公司 一种免疫调节剂
CN112341435B (zh) 2019-08-09 2021-10-22 成都先导药物开发股份有限公司 一种免疫调节剂
WO2021027729A1 (zh) 2019-08-09 2021-02-18 成都先导药物开发股份有限公司 一种免疫调节剂
WO2021027724A1 (zh) 2019-08-09 2021-02-18 成都先导药物开发股份有限公司 一种免疫调节剂
CN112341450B (zh) 2019-08-09 2022-05-17 成都先导药物开发股份有限公司 一种免疫调节剂
WO2021170627A1 (en) 2020-02-25 2021-09-02 UCB Biopharma SRL Difluorocyclohexyl derivatives as il-17 modulators
WO2021170631A1 (en) 2020-02-25 2021-09-02 UCB Biopharma SRL Difluorocyclohexyl derivatives as il-17 modulators
CA3179686A1 (en) 2020-04-07 2021-10-14 UCB Biopharma SRL Difluorocyclohexyl derivatives as il-17 modulators
WO2021204800A1 (en) 2020-04-07 2021-10-14 UCB Biopharma SRL Difluorocyclohexyl derivatives as il-17 modulators
MX2022013649A (es) * 2020-04-30 2023-02-01 Janssen Pharmaceutica Nv Métodos para identificar moduladores de la ruta de il-17.
KR20230019507A (ko) * 2020-04-30 2023-02-08 얀센 파마슈티카 엔.브이. Il-17의 조절제로서의 이미다조피리다진

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014039595A1 (en) * 2012-09-06 2014-03-13 Bristol-Myers Squibb Company Imidazopyridazine jak3 inhibitors and their use for the treatment of inflammatory and autoimmune diseases
WO2017087590A1 (en) * 2015-11-18 2017-05-26 Bristol-Myers Squibb Company Imidazopyridazine compounds useful as modulators of il-12, il-23 and/or ifn alpha responses
WO2019138017A1 (en) * 2018-01-15 2019-07-18 Ucb Biopharma Sprl Fused imidazole derivatives as il-17 modulators

Also Published As

Publication number Publication date
PE20230469A1 (es) 2023-03-14
US20220402922A1 (en) 2022-12-22
US11702422B2 (en) 2023-07-18
WO2021222404A1 (en) 2021-11-04
BR112022021962A2 (pt) 2023-03-28
JP2023524018A (ja) 2023-06-08
EP4143195B1 (en) 2025-05-21
ZA202212967B (en) 2024-06-26
KR20230019507A (ko) 2023-02-08
US12024524B2 (en) 2024-07-02
ECSP22091485A (es) 2022-12-30
TW202208367A (zh) 2022-03-01
JOP20220284A1 (ar) 2022-10-30
CN115884810A (zh) 2023-03-31
CN115884810B (zh) 2025-01-17
MX2022013647A (es) 2023-02-01
UY39188A (es) 2021-10-29
ES3036330T3 (en) 2025-09-17
US11691979B2 (en) 2023-07-04
IL297705A (en) 2022-12-01
US20230357254A1 (en) 2023-11-09
CA3181676A1 (en) 2021-11-04
AR121959A1 (es) 2022-07-27
EP4143195A1 (en) 2023-03-08
EP4143195C0 (en) 2025-05-21
JP7664947B2 (ja) 2025-04-18
CO2022017072A2 (es) 2022-12-09
AU2021264528A1 (en) 2023-01-19
US20230081548A1 (en) 2023-03-16

Similar Documents

Publication Publication Date Title
TWI874645B (zh) 作為il-17調節劑之咪唑并嗒類
CN114466849B (zh) 作为isoqc和/或qc酶的抑制剂的n-取代的-3,4-(稠合5-环)-5-苯基-吡咯烷-2-酮化合物
TWI606039B (zh) Ａｐｊ受體之三唑激動劑
TWI547480B (zh) Ｃ型肝炎病毒抑制劑
CN112105385A (zh) Irak降解剂和其用途
CN115066418A (zh) 具有抗炎性质的羧基衍生物
JP2021514982A (ja) インドール−２−カルボニル化合物及びｂ型肝炎治療のためのそれらの使用
TW201609725A (zh) 作為抗癌劑之新穎三環化合物
CN111315749A (zh) 新颖的二氢异噁唑化合物及其在治疗乙型肝炎中的用途
CN105085429B (zh) 芳杂环类衍生物及其在药物上的应用
TWI614250B (zh) 作為β－分泌酶抑制劑之環丙基稠合噻嗪－２－胺化合物及其使用方法
CN113056305A (zh) 化合物
WO2020108538A1 (zh) 含有磺酰基结构的RORγ抑制剂
CN118119613A (zh) 作为il-17调节剂的苯并咪唑
CN114667285A (zh) 抗病毒吡唑并吡啶酮化合物
WO2021218997A1 (zh) 取代的氮杂五元环类化合物及其在药物中的应用
CN113563245A (zh) 取代的吡咯烷类化合物及其在药物中的应用
EA049631B1 (ru) Имидазопиридазины в качестве модуляторов il-17
HK40106097A (zh) 羧基-苯并咪唑glp-1r调节化合物
HK40126737A (zh) 抗病毒吡唑并吡啶酮化合物
JP2024543028A (ja) ピルビン酸キナーゼモジュレーターとしてのフタラジン誘導体
HK40069881B (zh) 抗病毒吡唑并吡啶酮化合物
HK40069881A (zh) 抗病毒吡唑并吡啶酮化合物